OA12431A - Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. - Google Patents

Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. Download PDF

Info

Publication number
OA12431A
OA12431A OA1200300119A OA1200300119A OA12431A OA 12431 A OA12431 A OA 12431A OA 1200300119 A OA1200300119 A OA 1200300119A OA 1200300119 A OA1200300119 A OA 1200300119A OA 12431 A OA12431 A OA 12431A
Authority
OA
OAPI
Prior art keywords
oxidized
médicament
proteins
binding
protein
Prior art date
Application number
OA1200300119A
Other languages
English (en)
Inventor
Beate Kehrel
Martin Brodde
Original Assignee
Beate Kehrel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/de
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/de
Application filed by Beate Kehrel filed Critical Beate Kehrel
Publication of OA12431A publication Critical patent/OA12431A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
OA1200300119A 2000-10-20 2001-10-19 Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. OA12431A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (de) 2000-10-20 2000-10-20 Inhibierung der pathogenen Wirkung oxidierter Proteine
DE2001148624 DE10148624A1 (de) 2001-10-02 2001-10-02 Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten

Publications (1)

Publication Number Publication Date
OA12431A true OA12431A (en) 2006-04-19

Family

ID=26007431

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300119A OA12431A (en) 2000-10-20 2001-10-19 Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Country Status (14)

Country Link
EP (2) EP1328289B1 (es)
JP (1) JP4881535B2 (es)
AP (2) AP2034A (es)
AT (1) ATE406908T1 (es)
AU (1) AU2002215032A1 (es)
CA (1) CA2453140C (es)
CY (1) CY1110418T1 (es)
DE (1) DE50114289D1 (es)
DK (1) DK1328289T3 (es)
ES (1) ES2307662T3 (es)
HK (1) HK1057857A1 (es)
OA (1) OA12431A (es)
PT (1) PT1328289E (es)
WO (1) WO2002032445A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096368A1 (de) * 2003-04-25 2004-11-11 Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur Bekämpfung von hi-virus infektionen mit oxidierten blutproteinen
US7541340B2 (en) 2005-09-16 2009-06-02 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
DE102011003936A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
JPH05501258A (ja) * 1989-10-06 1993-03-11 ザ　ベス　イスラエル　ホスピタル　アソシエイション オキシダイズされたリポプロテインを使用した病状治療法及び装置
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5358707A (en) * 1990-01-08 1994-10-25 Schering Corporation Oxidized variants of GM-CSF
EP0539506A4 (en) * 1990-07-18 1993-11-24 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
NZ275054A (en) 1993-11-08 1997-04-24 Peptide Delivery Systems Pty L Diagnosing atherosclerosis or coronary artery disease using labelled composition which mimics essential features of an exogenous lipoprotein
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
WO1998059248A1 (en) 1997-06-20 1998-12-30 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and mda-modified low density lipoproteins
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
WO2000028072A1 (en) * 1998-11-06 2000-05-18 Emory University Biomarkers for oxidative stress
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III

Also Published As

Publication number Publication date
AU2002215032A1 (en) 2002-04-29
AP2003002795A0 (en) 2003-06-30
AP2009004857A0 (en) 2009-06-30
AP2034A (en) 2009-08-28
CA2453140A1 (en) 2002-04-25
JP4881535B2 (ja) 2012-02-22
AP2781A (en) 2013-10-31
EP1328289B1 (de) 2008-09-03
ATE406908T1 (de) 2008-09-15
PT1328289E (pt) 2008-12-10
EP1328289A2 (de) 2003-07-23
CY1110418T1 (el) 2015-04-29
DE50114289D1 (de) 2008-10-16
EP1994941A3 (de) 2012-07-25
WO2002032445A3 (de) 2003-04-17
WO2002032445A2 (de) 2002-04-25
ES2307662T3 (es) 2008-12-01
DK1328289T3 (da) 2008-12-15
JP2004511526A (ja) 2004-04-15
CA2453140C (en) 2016-01-05
EP1994941A2 (de) 2008-11-26
HK1057857A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
Woulfe REVIEW ARTICLES: Platelet G protein-coupled receptors in hemostasis and thrombosis
US6280731B1 (en) Antithrombotic agent and anti-von willebrand factor monoclonal antibody
CZ301524B6 (cs) Polypeptid z H. medicinalis, zpusob jeho prípravy a použití, farmaceutický prostredek, polynukleotid, expresní vektor, hostitelská bunka, protilátka a její použití
US7273925B1 (en) Methods and products for regulating lectin complement pathway associated complement activation
JP2002363100A (ja) 血栓性疾患防止のための医薬品
WO2000035483A1 (en) Methods and products for regulating lectin complement pathway associated complement activation
WO2007011682A2 (en) Methods and reagents for screening new drugs and for treating ion pump associated disorders and diseases
US8034769B2 (en) Oxidized proteins and oxidized protein inhibitor compositions and methods of use thereof
CA2453140C (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins and from the inhibition thereof
PL204449B1 (pl) DNA kodujący glikoproteinę VI
US20110236455A1 (en) Novel Regulators of the Innate Immune System
KR20010102130A (ko) 지혈 및 면역기능에 사용하기 위한 억제제
US20060153831A1 (en) Antithrombosis enzyme from the snake venom of Agkistrodon acutus
JP5232818B2 (ja) 酸化ｌｄｌ受容体に対する抗体を含んでなる医薬組成物
CN111870700B (zh) 十八烷基化修饰的r18-7aa多肽及其衍生多肽的应用
JP2006516024A (ja) α１β１インテグリンの誘導性リガンドおよび使用
DE10148624A1 (de) Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten
WO1998016548A1 (en) Thrombin receptor peptides and uses thereof
WO2016021894A1 (ko) Ｃｄ９ 항체를 유효성분으로 함유하는 세포노화 또는 노화 관련 질환 예방 또는 치료용 약학조성물
WO2000008050A9 (en) Dna encoding human monocyte-macrophage apolipoprotein b receptor gene and protein
Lo Investigating the functional roles of NBEAL2 in megakaryocytes and platelets
FR2895262A1 (fr) Inhibition de la reponse immunitaire anti-fviii
Ye The role of syntaxin and tomosyn in platelet secretion
EP2789631A1 (en) Compounds and methods for inhibition of binding of ICAM-4 to platelet integrin alphaIIbbeta3
Acquasaliente Coagulation protein factors: discovering novel interactions of thrombin